Literature DB >> 3501565

Altered antibody isotype in cystic fibrosis: impaired natural antibody response to polysaccharide antigens.

R B Moss1, Y P Hsu, P H Van Eede, A M Van Leeuwen, N J Lewiston, G De Lange.   

Abstract

Patients with cystic fibrosis (CF) have impaired natural (preinfection) IgG2 antibody responses to Pseudomonas aeruginosa lipopolysaccharide. To investigate the basis for this defect, we measured natural IgG and IgG1-4 antibody levels to Haemophilus influenzae type b polyribophosphate (PRP) and tetanus toxoid by enzyme-linked immunosorbent assay in 24 adult CF patients and 20 normal controls. Immunoglobulin heavy- and light-chain allotypes were determined on 146 Caucasian CF patients and 96 controls. The tetanus toxoid-specific IgG response was predominantly IgG1. CF and control subjects had similar IgG and IgG1 antibody levels. The PRP-specific IgG response was predominantly IgG2. In contrast to tetanus toxoid results, CF patients had lower geometric mean level of PRP-specific IgG compared to normal controls (p = 0.0036). ELISA results were confirmed by liquid-phase 3H-PRP-binding assay: CF patients had a geometric mean serum antibody level of 395 versus 922 ng/ml in controls (p = 0.0044). PRP-specific IgG2 levels were also depressed in CF patients (p = 0.03). CF patients had a lower prevalence of the A2m(2) allotype than the local racially matched control sample (p less than 0.025). Other allotype prevalences including G2m(n) and Km(1) were similar. Impaired IgG2 antibody responses to microbial polysaccharide surface antigens in CF patients might predispose them to persistent endobronchial infection and lead to production of nonopsonizing isotype responses. The potential role of A2m(2), coded for in the H chain locus on chromosome 14, is unknown, but could be related to mucosal IgA2 antibody responses.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501565     DOI: 10.1203/00006450-198712000-00020

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  7 in total

1.  IgG subclass antibodies to Pseudomonas aeruginosa in sera from patients with chronic Ps. aeruginosa infection investigated by ELISA.

Authors:  T Pressler; S S Pedersen; F Espersen; N Høiby; C Koch
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

2.  Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  S S Pedersen; F Espersen; N Høiby; T Jensen
Journal:  J Clin Microbiol       Date:  1990-04       Impact factor: 5.948

3.  Natural antibody affects survival of the spirochete Borrelia burgdorferi within feeding ticks.

Authors:  A A Belperron; L K Bockenstedt
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

4.  Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.

Authors:  I Eichler; L Joris; Y P Hsu; J Van Wye; R Bram; R Moss
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

Review 5.  Cystic fibrosis. Infection and immunity to Pseudomonas.

Authors:  R U Sorensen; R L Waller; J D Klinger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

6.  Immunoglobulin allotypes and IgG subclass antibody response to Pseudomonas aeruginosa antigens in chronically infected cystic fibrosis patients.

Authors:  T Pressler; J P Pandey; F Espersen; S S Pedersen; A Fomsgaard; C Koch; N Høiby
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

7.  Coxsackievirus B infections are common in Cystic Fibrosis and experimental evidence supports protection by vaccination.

Authors:  Virginia M Stone; Renata Utorova; Marta Butrym; Amir-Babak Sioofy-Khojine; Minna M Hankaniemi; Emma E Ringqvist; Marfa Blanter; Anirudra Parajuli; Terezia Pincikova; Björn Fischler; Ferenc Karpati; Vesa P Hytönen; Heikki Hyöty; Lena Hjelte; Malin Flodström-Tullberg
Journal:  iScience       Date:  2022-09-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.